

New real-world data confirms efficacy and safety of Pepaxti, presented at IMS Annual Meeting

Stockholm, September 1, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the publication of two real-world evidence (RWE) abstracts on Pepaxti at the International Myeloma Society (IMS) Annual Meeting, September 17–20 in Toronto, Canada.

[As previously communicated](#), the data were generated through treatment outcomes in real world settings from centers in Valencia, Spain and Bologna, Italy and underscore the growing interest in real-world clinical use of Pepaxti.

The Italian study reports an overall response rate (ORR) of 47 percent in a heavily pretreated patient population with relapsed or refractory multiple myeloma, confirming the efficacy previously demonstrated in the HORIZON trial with a similar safety profile. Importantly, the study demonstrated efficacy in patients treated with novel immunotherapies, underscoring the robust effectiveness of Pepaxti in daily clinical practice.

The Spanish study confirms the efficacy of Pepaxti in an even more heavily pretreated patient population where the majority of patients had been exposed to either anti-BCMA or anti-GPRC5D immunotherapy, generating data highly relevant to clinicians seeking guidance for treatment decisions.

Both studies confirm Pepaxti's favorable tolerability profile in real-world settings – a key consideration in multiple myeloma where safety challenges are common.

"These real-world data show that Pepaxti delivers compelling and meaningful outcomes for patients outside the controlled environment of clinical trials," says **Stefan Norin, Chief Medical Officer** at Oncopeptides. "The results confirm a positive clinical experience with Pepaxti, highlight its tolerability with manageable side effects, and provide highly relevant insights for physicians and payers in markets where treatment decisions increasingly rely on real-world evidence."

The abstracts are [available here](#). For further information, please visit www.oncopeptides.com.

For more information, please contact:

David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)

E-mail: ir@oncopeptides.com

Cell phone: +46 76 229 38 68

About Oncopeptides

Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.

The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.

Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.

The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.

For more information see: www.oncopeptides.com

About Pepaxti

Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.

Attachments

[New real-world data confirms efficacy and safety of Pepaxti, presented at IMS Annual Meeting](#)